SCHEMBL615020

SCHEMBL615020

Brc1ccc(OCc2ccccc2)cc1OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 8/20 0.59
ALOX5 P09917 1/20 0.58
LMNA P02545 1/20 0.52
CYP1A2 P05177 1/20 0.52
PTGS1 P23219 1/20 0.52
SLC6A2 P23975 1/20 0.52
CYP2C19 P33261 1/20 0.52
PTGS2 P35354 1/20 0.52
SLC6A3 Q01959 1/20 0.52
HIF1A Q16665 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
MAOA P21397 3/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
TOP1 P11387 1/20 0.49
LCK P06239 1/20 0.47
CYP3A4 P08684 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30628889 1.00 MAOB (0.59) MAOBALOX5LMNACYP1A2PTGS1
SCHEMBL31725937 0.88 MAOB (0.58) MAOBALOX5LMNAMAOAGAA
SCHEMBL6119729 0.88 MAOB (0.58) MAOBALOX5LMNAMAOAGAA
SCHEMBL31525501 0.88 MAOB (0.58) MAOBGAAMAPTRAB9ASMN1; SMN2
SCHEMBL7390468 0.88 MAOB (0.58) MAOBGAAMAPTRAB9ASMN1; SMN2
SCHEMBL17386359 0.88 MAOB (0.50) MAOBALOX5LMNACYP1A2PTGS1
SCHEMBL320716 0.87 MAPK1 (0.54) MAOBALOX5LMNARAB9ACYP3A4
SCHEMBL7400820 0.87 MAOB (0.57) MAOBGAAMAPTRAB9ASMN1; SMN2
SCHEMBL7778474 0.86 MAOB (0.59) MAOBALOX5LMNACYP1A2PTGS1
SCHEMBL3823883 0.85 MAOB (0.62) MAOBALOX5LMNACYP1A2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1121125-A1 PHARMACEUTICAL FORMULATIONS FOR USE IN ESTROGEN DEPRIVATION SYNDROME ELI LILLY AND COMPANY (US) 2001-08-08 EP claimed
WO-2000021535-A1 PHARMACEUTICAL FORMULATIONS FOR USE IN ESTROGEN DEPRIVATION SYNDROME ELI LILLY AND COMPANY (US) 2000-04-20 WO claimed
EP-4698520-A1 RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF Gandeeva Therapeutics, Inc. (US) 2026-02-25 EP disclosed
US-20250288553-A1 Antimicrobial Compositions and Uses for Treatment of Clostridioides difficile, Mycobacterium tuberculosis, and Enterococcus faecalis Infection THE UNIVERSITY OF TOLEDO 2025-09-18 US disclosed
WO-2024220708-A1 RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF GANDEEVA THERAPEUTICS, INC. (US) 2024-10-24 WO disclosed
WO-2023244764-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed
WO-2023239750-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
US-20230399282-A1 Series of Skin-Whitening (Lightening) Compounds UNIGEN, INC. (US) 2023-12-14 US disclosed
WO-2023215619-A2 ANTIMICROBIAL COMPOSITIONS AND USES FOR TREATMENT OF CLOSTRIDIOIDES DIFFICILE, MYCOBACTERIUM TUBERCULOSIS, AND ENTEROCOCCUS FAECALIS INFECTION UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2023-11-09 WO disclosed
US-11739040-B2 Series of skin-whitening (lightening) compounds UNIGEN, INC. (US) 2023-08-29 US disclosed
EP-3542780-B1 SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS UNIGEN INC (US) 2022-01-19 EP disclosed
US-4387229-A ANALGESICS, TRANQUILIZERS, SEDATIVES PFIZER INC. (US) 1983-06-07 US disclosed
US-4371720-A ANTIDIARRHEALS, ANTIEMETICS PFIZER INC. (US) 1983-02-01 US disclosed
US-4332942-A 3-(2-Hydroxy-4-(substituted)phenyl)azacycloalkanes as analgesics PFIZER, INC. (US) 1982-06-01 US disclosed
EP-0048572-A2 Substituted 2-hydroxyphenyl cycloalkanes and pharmaceutical compositions thereof PFIZER INC. (US) 1982-03-31 EP disclosed
US-4306097-A 3-[2-Hydroxy-4-(substituted)phenyl]-cycloalkanol analgesic agents PFIZER INC. (US) 1981-12-15 US disclosed
US-4284829-A Hydroxyalkyl and oxoalkyl substituted phenols as analgesics and sedatives PFIZER INC. (US) 1981-08-18 US disclosed
US-4283569-A Hydroxyalkyl and oxoalkyl substituted phenols as analgesics and sedatives PFIZER INC. (US) 1981-08-11 US disclosed
US-4263438-A 3-[2,4-(Disubstituted)-phenyl]azacycloalkanones as analgesics PFIZER INC. (US) 1981-04-21 US disclosed
US-4147872-A 3-[2-Hydroxy-4-(substituted)-phenyl]azacycloalkanes and derivatives thereof as analgesic agents and intermediates therefor PFIZER INC. (US) 1979-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11739040-B2 Series of skin-whitening (lightening) compounds TYR, TH, MAOB MAOB 3/4885ALOX5 301/4885LMNA 3351/4885
US-20250288553-A1 Antimicrobial Compositions and Uses for Treatment of Clostridioides difficile, Mycobacterium tuberculosis, and Enterococcus faecalis Infection VDR, CYP2R1, PTH1R MAOB 2348/4885ALOX5 1908/4885LMNA 1748/4885
US-20230399282-A1 Series of Skin-Whitening (Lightening) Compounds TYR, TH, MAOB MAOB 3/4885ALOX5 301/4885LMNA 3351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.